ArticleProceedings of the National Academy of Sciences of the United States of America2017
Proteoliposome-based full-length ZnT8 self-antigen for type 1 diabetes diagnosis on a plasmonic platform.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global bibliometric analysis of traditional Chinese medicine regulating gut microbiota in the treatment of diabetes from 2004 to 2024.Frontiers in pharmacology · 2025Pooled it
- Do-it-yourself protein arrays as high-throughput immunoassays enabled by confined droplets on patterned plasmonic chips.Nature communications · 2026Article
- Article
- A novel, high-performance, low-volume, rapid luciferase immunoprecipitation system (LIPS) assay to detect autoantibodies to zinc transporter 8.Clinical and experimental immunology · 2024Article
- Understanding Islet Autoantibodies in Prediction of Type 1 Diabetes.Journal of the Endocrine Society · 2023Review
- Label-free MXene-assisted field effect transistor for the determination of IL-6 in patients with kidney transplantation infection.Mikrochimica acta · 2023Article
- Cell-Surface Autoantibody Targets Zinc Transporter-8 (ZnT8) for In Vivo β-Cell Imaging and Islet-Specific Therapies.Diabetes · 2023Article
- Plasmonic nanosensors for point-of-care biomarker detection.Materials today. Bio · 2022Review
- Autoantibodies to Zinc Transporter 8 andJournal of diabetes research · 2022Article
- Gut Microbiota: An Important Player in Type 2 Diabetes Mellitus.Frontiers in cellular and infection microbiology · 2022Review
- Novel autoantibodies to the β-cell surface epitopes of ZnT8 in patients progressing to type-1 diabetes.Journal of autoimmunity · 2021Article
- Plasmonic Sensors for Extracellular Vesicle Analysis: From Scientific Development to Translational Research.ACS nano · 2020Review
- Article
- C-Terminal Domain of the Human Zinc Transporter hZnT8 Is Structurally Indistinguishable from Its Disease Risk Variant (R325W).International journal of molecular sciences · 2020Article
- Down-regulation of the islet-specific zinc transporter-8 (ZnT8) protects human insulinoma cells against inflammatory stress.The Journal of biological chemistry · 2019Article
- What has zinc transporter 8 autoimmunity taught us about type 1 diabetes?Diabetologia · 2019Review
- Molecular imaging of β-cells: diabetes and beyond.Advanced drug delivery reviews · 2019Review
- Genetic, Functional, and Immunological Study of ZnT8 in Diabetes.International journal of endocrinology · 2019Review
- Molecular Cancer Imaging in the Second Near-Infrared Window Using a Renal-Excreted NIR-II Fluorophore-Peptide Probe.Advanced materials (Deerfield Beach, Fla.) · 2018Article
- A subclass of serum anti-ZnT8 antibodies directed to the surface of live pancreatic β-cells.The Journal of biological chemistry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Identified as a major biomarker for type 1 diabetes (T1D) diagnosis, zinc transporter 8 autoantibody (ZnT8A) has shown promise for staging disease risk and disease diagnosis. However, existing assays for ZnT8 autoantibody (ZnT8A) are limited to detection by soluble domains of ZnT8, owing to difficulties in maintaining proper folding of a full-length ZnT8 protein outside its native membrane environment. Through a combined bioengineering and nanotechnology approach, we have developed a proteoliposome-based full-length ZnT8 self-antigen (full-length ZnT8 proteoliposomes; PLR-ZnT8) for efficient detection of ZnT8A on a plasmonic gold chip (pGOLD). The protective lipid matrix of proteoliposomes improved the proper folding and structural stability of full-length ZnT8, helping PLR-ZnT8 immobilized on pGOLD (PLR-ZnT8/pGOLD) achieve high-affinity capture of ZnT8A from T1D sera. Our PLR-ZnT8/pGOLD exhibited efficient ZnT8A detection for T1D diagnosis with ∼76% sensitivity and ∼97% specificity (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.